Sodium Hydroxide → 4-Methoxy-2-(4-methyl-2-(piperidin-1-yl)-6-p-tolylpyrimidin-5-yl)butanoic acid
反応式
[CH3:1][O:2][CH2:3][CH2:4][CH:5]([C:10]1[C:11]([CH3:29])=[N:12][C:13]([N:23]2[CH2:28][CH2:27][CH2:26][CH2:25][CH2:24]2)=[N:14][C:15]=1[C:16]1[CH:21]=[CH:20][C:19]([CH3:22])=[CH:18][CH:17]=1)[C:6]([O:8]C)=[O:7].[OH-].[Na+]>CO>[CH3:1][O:2][CH2:3][CH2:4][CH:5]([C:10]1[C:11]([CH3:29])=[N:12][C:13]([N:23]2[CH2:28][CH2:27][CH2:26][CH2:25][CH2:24]2)=[N:14][C:15]=1[C:16]1[CH:21]=[CH:20][C:19]([CH3:22])=[CH:18][CH:17]=1)[C:6]([OH:8])=[O:7]参加物
4
実験手順
This compound was prepared according to general method D from methyl 4-methoxy-2-(4-methyl-2-(piperidin-1-yl)-6-p-tolylpyrimidin-5-yl)butanoate (0.018 g; 0.045 mmol), sodium hydroxide 10N (0.045 mL; 0.45 mmol) in methanol (0.4 mL) to afford 0.007 g (38%) of the title compound as a white solid.